Characteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients

Andrea Váncsa, I. Csípő, J. Németh, K. Dévényi, L. Gergely, K. Dankó

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

The strongest predictive factor for the development of interstitial lung disease (ILD) in myositis (IIM) patients is the presence of different antisynthetase antibodies. The aim of this study was to compare the clinical characteristics, radiological findings and therapeutic response between the anti-SS-A positive and negative antisynthetase syndrome (ASS) patients. A prospective study of 315 IIM patients was conducted including 27 anti-Jo-1 positive ASS patients. Mean disease duration was 46.6 (range 4-198) months. All patients fulfilled the classification criteria for IIM. All patients underwent chest radiography, pulmonary function tests and HRCT at he time of diagnosis and 6 months after the immunosuppressive therapy. Routine laboratory tests, RF, ANA, anti-ENA, anti-SS-A, anti-histidyl-transfer RNA antibody (Jo-1) measurements were performed in all patients. ILD was found to be present in 70.4% of ASS patients. The anti-SS-A negative ASS group had a more frequent association with alveolitis and responded well to immunosuppressive therapy (p <0.05). HRCT scan showed more fibrosis in the SS-A positive group. 15.8% of patients died due to pulmonary or cardiac complications. In conclusion, coexistence of anti-SS-A and anti-Jo-1 antibody may be a good predictor for a more coarse and severe ILD in IIM patients who require a more aggressive approach in therapy.

Original languageEnglish
Pages (from-to)989-994
Number of pages6
JournalRheumatology International
Volume29
Issue number9
DOIs
Publication statusPublished - Jun 2009

Fingerprint

Myositis
Interstitial Lung Diseases
Immunosuppressive Agents
Respiratory Function Tests
Therapeutics
Transfer RNA
Radiography
Fibrosis
Thorax
Prospective Studies
Lung

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Characteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients. / Váncsa, Andrea; Csípő, I.; Németh, J.; Dévényi, K.; Gergely, L.; Dankó, K.

In: Rheumatology International, Vol. 29, No. 9, 06.2009, p. 989-994.

Research output: Contribution to journalArticle

@article{cb9abf39cfbc4995864ae8d74c03ad93,
title = "Characteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients",
abstract = "The strongest predictive factor for the development of interstitial lung disease (ILD) in myositis (IIM) patients is the presence of different antisynthetase antibodies. The aim of this study was to compare the clinical characteristics, radiological findings and therapeutic response between the anti-SS-A positive and negative antisynthetase syndrome (ASS) patients. A prospective study of 315 IIM patients was conducted including 27 anti-Jo-1 positive ASS patients. Mean disease duration was 46.6 (range 4-198) months. All patients fulfilled the classification criteria for IIM. All patients underwent chest radiography, pulmonary function tests and HRCT at he time of diagnosis and 6 months after the immunosuppressive therapy. Routine laboratory tests, RF, ANA, anti-ENA, anti-SS-A, anti-histidyl-transfer RNA antibody (Jo-1) measurements were performed in all patients. ILD was found to be present in 70.4{\%} of ASS patients. The anti-SS-A negative ASS group had a more frequent association with alveolitis and responded well to immunosuppressive therapy (p <0.05). HRCT scan showed more fibrosis in the SS-A positive group. 15.8{\%} of patients died due to pulmonary or cardiac complications. In conclusion, coexistence of anti-SS-A and anti-Jo-1 antibody may be a good predictor for a more coarse and severe ILD in IIM patients who require a more aggressive approach in therapy.",
author = "Andrea V{\'a}ncsa and I. Cs{\'i}pő and J. N{\'e}meth and K. D{\'e}v{\'e}nyi and L. Gergely and K. Dank{\'o}",
year = "2009",
month = "6",
doi = "10.1007/s00296-009-0884-9",
language = "English",
volume = "29",
pages = "989--994",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Verlag",
number = "9",

}

TY - JOUR

T1 - Characteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients

AU - Váncsa, Andrea

AU - Csípő, I.

AU - Németh, J.

AU - Dévényi, K.

AU - Gergely, L.

AU - Dankó, K.

PY - 2009/6

Y1 - 2009/6

N2 - The strongest predictive factor for the development of interstitial lung disease (ILD) in myositis (IIM) patients is the presence of different antisynthetase antibodies. The aim of this study was to compare the clinical characteristics, radiological findings and therapeutic response between the anti-SS-A positive and negative antisynthetase syndrome (ASS) patients. A prospective study of 315 IIM patients was conducted including 27 anti-Jo-1 positive ASS patients. Mean disease duration was 46.6 (range 4-198) months. All patients fulfilled the classification criteria for IIM. All patients underwent chest radiography, pulmonary function tests and HRCT at he time of diagnosis and 6 months after the immunosuppressive therapy. Routine laboratory tests, RF, ANA, anti-ENA, anti-SS-A, anti-histidyl-transfer RNA antibody (Jo-1) measurements were performed in all patients. ILD was found to be present in 70.4% of ASS patients. The anti-SS-A negative ASS group had a more frequent association with alveolitis and responded well to immunosuppressive therapy (p <0.05). HRCT scan showed more fibrosis in the SS-A positive group. 15.8% of patients died due to pulmonary or cardiac complications. In conclusion, coexistence of anti-SS-A and anti-Jo-1 antibody may be a good predictor for a more coarse and severe ILD in IIM patients who require a more aggressive approach in therapy.

AB - The strongest predictive factor for the development of interstitial lung disease (ILD) in myositis (IIM) patients is the presence of different antisynthetase antibodies. The aim of this study was to compare the clinical characteristics, radiological findings and therapeutic response between the anti-SS-A positive and negative antisynthetase syndrome (ASS) patients. A prospective study of 315 IIM patients was conducted including 27 anti-Jo-1 positive ASS patients. Mean disease duration was 46.6 (range 4-198) months. All patients fulfilled the classification criteria for IIM. All patients underwent chest radiography, pulmonary function tests and HRCT at he time of diagnosis and 6 months after the immunosuppressive therapy. Routine laboratory tests, RF, ANA, anti-ENA, anti-SS-A, anti-histidyl-transfer RNA antibody (Jo-1) measurements were performed in all patients. ILD was found to be present in 70.4% of ASS patients. The anti-SS-A negative ASS group had a more frequent association with alveolitis and responded well to immunosuppressive therapy (p <0.05). HRCT scan showed more fibrosis in the SS-A positive group. 15.8% of patients died due to pulmonary or cardiac complications. In conclusion, coexistence of anti-SS-A and anti-Jo-1 antibody may be a good predictor for a more coarse and severe ILD in IIM patients who require a more aggressive approach in therapy.

UR - http://www.scopus.com/inward/record.url?scp=67349084656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349084656&partnerID=8YFLogxK

U2 - 10.1007/s00296-009-0884-9

DO - 10.1007/s00296-009-0884-9

M3 - Article

C2 - 19266202

AN - SCOPUS:67349084656

VL - 29

SP - 989

EP - 994

JO - Rheumatology International

JF - Rheumatology International

SN - 0172-8172

IS - 9

ER -